HUP0203676A2 - Eljárás és gyógyszerészeti készítmény diabetes kezeléséhez - Google Patents

Eljárás és gyógyszerészeti készítmény diabetes kezeléséhez

Info

Publication number
HUP0203676A2
HUP0203676A2 HU0203676A HUP0203676A HUP0203676A2 HU P0203676 A2 HUP0203676 A2 HU P0203676A2 HU 0203676 A HU0203676 A HU 0203676A HU P0203676 A HUP0203676 A HU P0203676A HU P0203676 A2 HUP0203676 A2 HU P0203676A2
Authority
HU
Hungary
Prior art keywords
sulfatide
treatment
diabetes
pharmaceutical composition
isoform
Prior art date
Application number
HU0203676A
Other languages
English (en)
Inventor
Karsten Buschard
Pam Fredman
Original Assignee
A+Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A+Science Invest Ab filed Critical A+Science Invest Ab
Publication of HUP0203676A2 publication Critical patent/HUP0203676A2/hu
Publication of HUP0203676A3 publication Critical patent/HUP0203676A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmányban a diabetikus állapot kezeléséhez alkalmazhatógyógyszerészeti készítmény termeléséhez legalább egy szulfatidizoforma felhasználását tették közzé. A találmány tárgya a diabetikusállapot kezelési eljárása is, amelyben a betegbe beadott legalább egyszulfatid izoforma terápiásan hatékony mennyiségű, és a szóban forgólegalább egy szulfatid izoforma betegbe beadva a szulfatid anyagcserétúgy befolyásolja, hogy a szulfatid mennyiségét növeli. A szóban forgóizoformák zsírsavláncukban előnyösen 8-24 szénatomosak, előnyösebben a14-18 szénatomosak, és még előnyösebben 16 szénatomos izoformák. Ó
HU0203676A 2000-01-27 2001-01-29 Pharmaceutical composition and method for treatment of diabetes HUP0203676A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0000258A SE0000258D0 (sv) 2000-01-27 2000-01-27 Pharmaceutical preparation and method for treatment of diabetes
PCT/SE2001/000169 WO2001054700A1 (en) 2000-01-27 2001-01-29 Pharmaceutical preparation and method for treatment of diabetes

Publications (2)

Publication Number Publication Date
HUP0203676A2 true HUP0203676A2 (hu) 2003-04-28
HUP0203676A3 HUP0203676A3 (en) 2003-08-28

Family

ID=20278246

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203676A HUP0203676A3 (en) 2000-01-27 2001-01-29 Pharmaceutical composition and method for treatment of diabetes

Country Status (18)

Country Link
US (1) US6908904B2 (hu)
EP (1) EP1320372B1 (hu)
JP (1) JP2003520818A (hu)
KR (1) KR20030005168A (hu)
CN (1) CN1396831A (hu)
AT (1) ATE310525T1 (hu)
AU (1) AU778994B2 (hu)
BR (1) BR0107871A (hu)
CA (1) CA2398206A1 (hu)
CZ (1) CZ20022519A3 (hu)
DE (1) DE60115263D1 (hu)
HU (1) HUP0203676A3 (hu)
MX (1) MXPA02007196A (hu)
PL (1) PL356778A1 (hu)
RU (1) RU2266123C2 (hu)
SE (1) SE0000258D0 (hu)
SK (1) SK10762002A3 (hu)
WO (1) WO2001054700A1 (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000258D0 (sv) 2000-01-27 2000-01-27 A & Science Invest Ab Pharmaceutical preparation and method for treatment of diabetes
US20110118197A1 (en) * 2005-09-29 2011-05-19 Vipin Kumar Chaturvedi Prevention of hepatic ischemic reperfusion injury by administration of sulfatides
US9821035B2 (en) 2012-08-22 2017-11-21 Regimmune Corporation Preparation for preventing or treating type I diabetes
WO2019238841A1 (en) * 2018-06-15 2019-12-19 Københavns Universitet Coating medical devices to avoid fibroblast overgrowth

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK84691D0 (da) * 1991-05-07 1991-05-07 Karsten Buschard Visse glycolipider og specifikke catchere for disse til anvendelse ved profylaxe eller terapi af diabetes, og/eller dermed forbundne komplikationer samt anvendelse af saadanne glycolipider til detektion af oe-celle-antistoffer (ica) i et individ og anvendelse af saadanne catchere til detektion af langerhans-oe-celler i pancreas-praeparater
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
SE9601817D0 (sv) * 1996-05-13 1996-05-13 Karsten Buschard Novel glycolipid complexex and their uses
DE19700774A1 (de) * 1997-01-13 1998-07-16 Hoechst Ag Antiadhäsive Sulfatid-Mimetika
EP0988860B1 (en) * 1997-04-10 2005-01-12 Kirin Beer Kabushiki Kaisha Use of a-glycosylceramides for the manufacture of a therapeutic agent for autoimmune diseases
JP2001527046A (ja) * 1997-12-30 2001-12-25 エイプラス サイエンス インベスト アーベー ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および／または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー
SE0000258D0 (sv) 2000-01-27 2000-01-27 A & Science Invest Ab Pharmaceutical preparation and method for treatment of diabetes

Also Published As

Publication number Publication date
DE60115263D1 (de) 2005-12-29
EP1320372B1 (en) 2005-11-23
US6908904B2 (en) 2005-06-21
SK10762002A3 (sk) 2003-07-01
CN1396831A (zh) 2003-02-12
MXPA02007196A (es) 2003-01-28
AU778994B2 (en) 2004-12-23
EP1320372A1 (en) 2003-06-25
HUP0203676A3 (en) 2003-08-28
WO2001054700A1 (en) 2001-08-02
RU2002122982A (ru) 2004-03-20
AU3069101A (en) 2001-08-07
ATE310525T1 (de) 2005-12-15
CZ20022519A3 (cs) 2003-06-18
SE0000258D0 (sv) 2000-01-27
CA2398206A1 (en) 2001-08-02
BR0107871A (pt) 2002-11-05
RU2266123C2 (ru) 2005-12-20
PL356778A1 (en) 2004-07-12
US20030004115A1 (en) 2003-01-02
KR20030005168A (ko) 2003-01-17
JP2003520818A (ja) 2003-07-08

Similar Documents

Publication Publication Date Title
HUP0401590A2 (hu) Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
DE69930252D1 (de) Verwendung von tetracyclinen zur behandlung von störungen der meibomschen drüsen
ATE481970T1 (de) Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
EA200500782A1 (ru) Лечение геморрагического шока
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
HK1065941A1 (en) Use of a nicotinic acid alkyl ester containing an alkyl chain from 8 to 22 carbon atoms for the preparation of a medicament for increasing leptin levels in a subject
DE602004030222D1 (de) 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
HUP0401867A2 (hu) A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
DE602005010213D1 (de) Verfahren zur behandlung und diagnose von atemstörungen im schlaf mit zonisamid und mittel zur durchführung des verfahrens
DE60042215D1 (de) Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ATE302025T1 (de) Vorrichtungen zur behandlung und diagnose des restless leg syndroms
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
ATE296098T1 (de) Verwendung von topiramat zur behandlung und diagnostizierung von atemstörungen während des schlafens und mittel zur durchführung der behandlung und diagnose
BRPI0409151A (pt) uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos
HUP0203676A2 (hu) Eljárás és gyógyszerészeti készítmény diabetes kezeléséhez
Yilmaz et al. Comparison of levo-bupivacaine and lidocaine for postoperative analgesia following septoplasty
DE69822810D1 (de) Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x